What is it about?
Help us with understanding correct antibiotic choice, and a comparison of data with other countries
Featured Image
Why is it important?
Follow-up resistance burden, and evolutionary trends of resistance on Gram-negatives
Perspectives
Follow-up Taiwan's resistance burden in the future
Shio-Shin Jean
Read the Original
This page is a summary of: In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART), Infection and Drug Resistance, October 2018, Dove Medical Press,
DOI: 10.2147/idr.s175679.
You can read the full text:
Contributors
The following have contributed to this page
